Only 20% of ovarian cancers are detected early, mostly because there are seldom symptoms that don’t mimic common bladder, bowel or gastrointestinal issues. However, a recent Penn Today article noted the FDA approval of Cytalux, an imaging drug for ovarian cancer that aims to improve early detection, and therefore survival rates.
FDA Approves ‘Glowing Tumor’ Imaging Drug
The drug is attracted to ovarian cancer tissue and illuminates under fluorescent light to pinpoint cancer.
Dec 9, 2021
Recommended
Recommended
Recommended
Break out of the ordinary: see what’s new in life sciences packaging
<strong>At PACK EXPO Las Vegas, you’ll see machinery in action and new tech from 2,300 suppliers, collaborate with experts and explore transformative solutions. Join us in September to experience a breakthrough for life sciences products.</strong>
REGISTER NOW & SAVE!
Pharmaceutical Innovations Report
Discover the latest breakthrough packaging technologies shaping the pharmaceutical sector. This report dives into cutting-edge innovations, from smart containers that enhance patient safety to eco-friendly materials poised to transform the industry’s sustainability practices. All from PACK EXPO. Learn how forward-thinking strategies are driving efficiency and redefining what’s possible in pharma packaging.
Learn More
